

RESEARCH ON INVASIVE CLINICAL CARDIOLOGY

PUBLICATIONS

- * Ageno W, Buller HR, Falanga A, Hacke W, Hendriks J, Lobban T, Merino J, Milojevic IS, Moya F, van der Worp HB, Randall G, Tsioufis K, Verhamme P, Camm AJ. Managing reversal of direct oral anticoagulants in emergency situations Anticoagulation Education Task Force White Paper. *Thromb Haemostasis*. 2016;116(6):1003-10. Article. IF: 5.627; D1
- * Akerstrom F, Pachon M, García-Fernández FJ, Salvador-Montañés O, Jensen-Urstad M, Puchol A, Peinado R, Salgado R, Insulander P, Rodríguez-Padial L, Arias MA. Number of beats in the transition zone with fixed SA interval during right ventricular overdrive pacing determines accessory pathway location in orthodromic reentrant tachycardia. *Pace*. 2016;39(1):21-7. Article. IF: 1.486; Q3
- * Alfonso F, Pérez-Vizcaíno MJ, del Blanco BG, García-Touchard A, López-Mínguez JR, Masotti M, Zueco J, Melgares R, Mainar V, Moreno R, Domínguez A, Sanchis J, Bethencourt A, Moreu J, Cequier A, Martí V, Otaegui I, Bastante T, Gonzalo N, Jiménez-Quevedo P, Cárdenas A, Fernández C. Everolimus-eluting stents in patients with bare-metal and drug-eluting in-stent restenosis results from a patient-level pooled analysis of the RIBS IV and V Trials. *Circ-Cardiovasc Inte*. 2016;9(7):e003479. Article. IF: 7.198; D1
- * Ambrosio G, Komajda M, Mugelli A, López-Sendón J, Tamargo J, Camm J. Management of stable angina: A commentary on the European Society of Cardiology guidelines. *Eur J Prev Cardiol*. 2016;23(13):1401-12. Editorial Material. IF: 3.606; Q2
- * Anguera I, García-Alberola A, Dallaglio P, Toquero J, Pérez L, Martínez JG, Peinado R, Rubín JM, Brugada J, Cequier A. Shock reduction with long-term quinidine in patients with brugada syndrome and malignant ventricular arrhythmia episodes. *J Am Coll Cardiol*. 2016;67(13):1653-4. Letter. IF: 19.896; D1
- * Arbel Y, FitzGerald G, Yan AT, Tan MK, Fox KAA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Budaj A, López-Sendón J, Avezum A, Granger CB, Goodman SG. Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. *Int J Cardiol*. 2016;218:291-7. Article. IF: 6.189; Q1
- * Aroca A, Polo L, Sánchez R, Bret M, González A, Rey J, Ruiz J, Peña N, Pérez N, González A, Sánchez-Recalde A, Villagrà F. Single ventricle

surgery in adulthood. A considered decision. *Cir Cardiovasc*. 2016;23(2):80-6. Article. IF: Not Indexed

- * Arroyo-Ucar E, Moreno R, del Prado S, López T, Sánchez-Recalde A, Orbe LC, Jiménez-Valero S, Galeote G, Ramírez MU, Davia RG, Plaza I, Mesa JM, López-Sendón JL. Echogenic mobile images in intraprocedural three-dimensional transesophageal echocardiographic monitoring during percutaneous aortic valve implantation: Incidence, characteristics and clinical implications. *Rev Port Cardiol*. 2016;35(3):133-8. Article. IF: 1.195; Q4
- * Barrios V, Escobar C. Blood pressure goals revisited. *J Hypertens*. 2016;34(7):1444-5. Letter. IF: 4.085; Q1
- * Barrios V, Escobar C. Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. *Future Cardiol*. 2016;12(4):449-66. Article. IF: Not Indexed
- * Barrios V, Escobar C. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. *Future Cardiol*. 2016;12(4):419-33. Article. IF: Not Indexed
- * Barrios V, Escobar C. Improving cardiovascular protection: focus on a cardiovascular polypill. *Future Cardiol*. 2016;12(2):181-96. Review. IF: Not Indexed
- * Bohm M, Lloyd SM, Ford I, Borer JS, Ewen S, Laufs U, Mahfoud F, López-Sendón J, Ponikowski P, Tavazzi L, Swedberg K, Komajda M. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. *Eur J Heart Fail*. 2016;18(6):672-83. Article. IF: 6.968; D1
- * Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Ophuis TO, Budaj A, Goto S, López-Sendón J, Díaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. *Eur Heart J*. 2016;37(14):1133-42. Article. IF: 19.651; D1
- * Bonaca MP, Bhatt DL, Storey RF, Steg G, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Spinar J, Aylward P, Corbalaá R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MS. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. *J Am Coll Cardiol*. 2016;67(23):2719-28. Article. IF: 19.896; D1
- * Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GYH, Steg PG, ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ripoll EF, Oldgren J, Hohnloser SH, (López Sendón JL). Design and rationale of the RE-DUAL PCI Trial: A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary

intervention with stenting. Clin Cardiol. 2016;39(10):555-64. Article. IF: 2.757; Q2

- * Caro-Codón J, Galeote G, Álvarez-Ortega C, Moreno R, López-Sendón JL. A marble in the heart. JACC-Cardiovasc Inte. 2016;9(24):2573-4. Editorial Material. IF: 8.841; D1
- * Caro-Codón J, Jiménez-Valero S, Galeote G, Sánchez-Recalde A, Moreno R. Radiation-induced coronary artery disease: Useful insights from OCT. Int J Cardiol. 2016;202:535-6. Letter. IF: 6.189; Q1
- * Caro-Codón J, Valbuena-López S, Álvarez-Ortega C, Moreno-Yanguela M, Moreno R. Rapid pacing-induced massive mitral regurgitation during transcatheter aortic valve implantation. Circ J. 2016;80(3):748-9. Editorial Material. IF: 3.544; Q2
- * Conde AC, Martín DM, González-Gallarza RD, Esteban VA, Bueno MM, Marimón XGM, Senén AB, Murga N, Abeytua M. Vascular risk and cardiac rehabilitation 2015: A selection of topical issues. Rev Esp Cardiol. 2016;69(3):294-9. Article. IF: 4.485; Q2
- * Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu GM, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, López-Sendón J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M. Andexanet alfa for acute major bleeding associated with factor XA Inhibitors. New Engl J Med. 2016;375(12):1131-41. Article. IF: 72.406; D1
- * Chan WK, Goodman SG, Brieger D, Fox KAA, Gale CP, Chew DP, Udell JA, López-Sendon J, Huynh T, Yan RT, Singh SM, Yan AT. Clinical characteristics, management, and outcomes of acute coronary syndrome in patients with right bundle branch block on presentation. Am J Cardiol. 2016;117(5):754-9. Article. IF: 3.398; Q2
- * Dallaglio PD, Anguera I, Jiménez-Candil J, Peinado R, García-Seara J, Arcocha MF, Macías R, Herreros B, Quesada A, Hernández-Madrid A, Álvarez M, di Marco A, Filgueiras D, Matía R, Cequier A, Sabate X. Impact of previous cardiac surgery on long-term outcome of cavotricuspid isthmus-dependent atrial flutter ablation. Europace. 2016;18(6):873-80. Article. IF: 4.53; Q1
- * Danchin N, Lettino M, Zeymer U, Widimsky P, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, de Luca L, Dorler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Luscher TF, Matter CM, Montalescot G, Radovanovic D, Sendón JL, Tousek P, Weidinger F, Weston CFM, Zaman A, Andell P, Li J, Jukema JW. Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):152-67. Article. IF: Not Indexed
- * de Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, Hanna M, Held C, Hohnloser S, Hylek EM, Lanus F, Lopes RD, López-Sendon J, Renda G, Horowitz J, Granger CB, Wallentin L. History of

bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. *Am Heart J*. 2016;175:175-83. Article. IF: 4.436; Q2

- * Díaz SD, Salicio ER, Valbuena-López SC, Peña MFV, Ramírez-Valdiris U, Guzmán-Martínez G. Multidetector computed tomography usefulness in infective endocarditis. *Rev Esp Cardiol*. 2016;69(4):442-5. Letter. IF: 4.485; Q2
- * Escobar C, Barrios V, Prieto L. Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled. *Eur J Intern Med*. 2016;30:E17-8. Letter. IF: 2.96; Q1
- * Esteve-Pastor MA, García-Fernández A, Macías M, Sogorb F, Valdés M, Roldán V, Muñiz J, Badimón L, Roldán I, Bertomeu-Martínez V, Cequier A, Lip GYH, Anguita M, Marín F. Is the ORBIT bleeding risk score superior to the HAS-BLED score in anticoagulated atrial fibrillation patients? *Circ J*. 2016;80(10):2102-8. Article. IF: 3.544; Q2
- * Esteve-Pastor MA, Marín F, Bertoméu-Martínez V, Roldán-Rabadán I, Cequier-Fillat A, Badimón L, Muñiz-García J, Valdés M, Anguita-Sánchez M. Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS(2) and CHA(2)DS(2)-VASc scores. *Intern Med J*. 2016;46(5):583-9. Article. IF: 1.902; Q2
- * Estrada A, Doiny D, Merino JL. Perimitral atrial flutter ablation by transaortic radiofrequency application. *Europace*. 2016;18(7):1037. Article. IF: 4.53; Q1
- * Fernández-Lozano I, Brugada J, Alzueta J, Arbelo E, Arribas F, García-Bolao I, Merino JL, Olalla JJ, Osca J, Quesada A, Anguita M, Cequier A, Alfonso F, Badimón L, Barrabés JA, Lozano IF, de Diego JJG, Padial LR, San Román JA, Sánchez PL, Sanchis J, Sionis A. Comments on the 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Rev Esp Cardiol*. 2016;69(2):94-101. Editorial Material. IF: 4.485; Q2
- * Ferreira-González I, Abu-Assi E, Arias MA, Gallego P, Sánchez-Recalde A, Avanzas P, Bayes-Genis A, de Isla LP, Sanchis J. Revista Española de Cardiología: Current position and future directions. *Rev Esp Cardiol*. 2016;69(3):327-36. Editorial Material. IF: 4.485; Q2
- * Fontenla A, Martínez-Ferrer JB, Alzueta J, Vinolas X, García-Alberola A, Brugada J, Peinado R, Sancho-Tello MJ, Cano A, Fernández-Lozano I. Incidence of arrhythmias in a large cohort of patients with current implantable cardioverter-defibrillators in Spain: results from the UMBRELLA Registry. *Europace*. 2016;18(11):1726-34. Article. IF: 4.53; Q1
- * García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sánchez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL. Cardiovascular management of patients with chronic myeloid leukemia from a

multidisciplinary perspective, and proposing action protocol by consensus meeting. *Med Clin-Barcelona*. 2016;146(12):561.e1-8. Article. IF: 1.125; Q3

- * Gemma D, Gómez RM, de Bobadilla JF, García GG, Fernández TL, López-Mínguez JR, López-Sendón JL. Percutaneous balloon mitral valvuloplasty and closure of the left atrial appendage: Synergy of two procedures in one percutaneous intervention. *Rev Port Cardiol*. 2016;35(11):617. Article. IF: 1.195; Q4
- * Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernández V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GYH. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. *Lancet*. 2016;388(10055):1995-2003. Article. IF: 47.831; D1
- * Gómez-Lara J, Salvatella N, Gonzalo N, Hernández-Hernández F, Fernández-Nofreries E, Sánchez-Recalde A, Bastante T, Marcano A, Romaguera R, Ferreiro JL, Roura G, Teruel L, Ariza-Sole A, Miranda-Guardiola F, García-Abad VR, Gómez-Hospital JA, Alfonso F, Cequier A. IVUS-guided treatment strategies for definite late and very late stent thrombosis. *Eurointervention*. 2016;12(11):E1355-65. Article. IF: 5.165; Q1
- * Green AS, Lorite NM, Bueno H, Payeras AC, Molina BD, Juanatey JRG, Urioste LMR, Gómez JLZ, Bonet LA, Sole AA, Freire RB, Rodríguez JLL, de Sa EL, Fernández SL, Asenjo RM, Pérez SM, Figal DP, Cubero JS, Román AV, Calvar JAS, Manterola FA, Ynsaurriaga FA, Masip AE, Gonzalez IF, Navarro MJ, Ortuno FM, de Isla LP, Padial LR, Fernández PLS, Green AS, García RV. Comments on the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Rev Esp Cardiol*. 2016;69(12):1119-25. Editorial Material. IF: 4.485; Q2
- * Hagstrom E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbahn A, Wallentin L, (López Sendón JL). Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. *Eur Heart J*. 2016;37(16):1325-33. Article. IF: 19.651; D1
- * Hernández JMD, Moreno R, Lee DH, García del Blanco B, San Martín JC, García Blas S, Serra García V, Gaviria K, García I, Zueco J. The routine use of surgical exposure approach for trans-femoral implantation of the balloon expandable aortic prosthesis is associated to a low rate of vascular complications. *J Cardiovasc Surg*. 2016;57(4):615-9. Article. IF: 2.179; Q2
- * Hernández-Enríquez M, Andrea R, Brugaletta S, Jiménez-Quevedo P, Hernández-García JM, Trillo R, Larman M, Fernández-Avilés F, Vázquez-González N, Iñíguez A, Zueco J, Ruiz-Salmerón R, del Valle R, Molina E, del Blanco BG, Berenguer A, Valdés M, Moreno R, Urbano-Carrillo C,

Hernández-Antolín R, Gimeno F, Cequier A, Cruz I, López-Mínguez JR, Aramendi JJ, Sánchez A, Goicolea J, Albarran A, Díaz JF, Navarro F, Moreu J, Morist A, Fernández-Nofrerías E, Fernández-Vázquez F, Ten F, Mainar V, Mari B, Saenz A, Alfonso F, Diarte JA, Sancho M, Lezaun R, Arzamendi D, Sabate M. Puncture versus surgical cutdown complications of transfemoral aortic valve implantation (from the Spanish TAVI Registry). *Am J Cardiol.* 2016;118(4):578-84. Article. IF: 3.398; Q2

- * Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L, (López Sendón JL). Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. *Heart.* 2016;102(7):508-17. Article. IF: 6.059; Q1
- * Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, López-Sendón JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time insights from the ARISTOTLE randomized clinical trial. *JAMA Cardiol.* 2016;1(4):451-60. Article. IF: Not Indexed
- * Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Cavaliere M, Iekushi K, Yamanaka S, (Merino JL). Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation - Subgroup analysis of J-ROCKET AF. *J Cardiol.* 2016;68(42891):523-8. Article. IF: 2.732; Q2
- * Hori M, Ohashi Y, Pan GH, Kato M, Kajikawa M, (Merino JL). Point-of-care device for warfarin monitoring used in the J-ROCKET AF Study. *Circ J.* 2016;80(6):1488-90. Letter. IF: 3.544; Q2
- * Johansson A, Eriksson N, Lindholm D, Varenhorst C, James S, Syvanen AC, Axelsson T, Siegbahn A, Barratt BJ, Becker RC, Himmelmann A, Katus HA, Steg PG, Storey RF, Wallentin L, (López Sendón JL). Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. *Hum Mol Genet.* 2016;25(7):1447-56. Article. IF: 5.34; Q2
- * Jolly SS, Cairns JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, Kedev S, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemela K, Bernat I, Cantor WJ, Cheema AN, Steg PG, Welsh RC, Sheth T, Bertrand OF, Avezum A, Bhindi R, Natarajan MK, Horak D, Leung RCM, Kassam S, Rao SV, El-Omar M, Mehta SR, Velianou JL, Pancholy S, Dzavik V. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. *Lancet.* 2016;387(10014):127-35. Article. IF: 47.831; D1
- * Kotseva K, Wood D, de Bacquer D, de Backer G, Ryden L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Conde AC, Cifkova R, Deckers JW, de Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milicic D,

- Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Stork S, Tokgozoglu L, Vulic D. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *Eur J Prev Cardiol.* 2016;23(6):636-48. Article. IF: 3.606; Q2
- * Lesiak M, Araszkievicz A, Grajek S, Colombo A, Lalmand J, Carstensen S, Namiki A, Tobaru T, Merkely B, Moreno R, Barbato E, Wijns W, Saito S. Long coronary lesions treated with thin strut bioresorbable polymer drug eluting stent: Experience from multicentre randomized CENTURY II study. *J Interv Cardiol.* 2016;29(1):47-56. Article. IF: 1.88; Q3
 - * Lillo-Castellano JM, Marina-Breyse M, Gómez-Gallanti A, Martínez-Ferrer JB, Alzueta J, Pérez-Álvarez L, Alberola A, Fernández-Lozano I, Rodríguez A, Porro R, Anguera I, Fontenla A, González-Ferrer JJ, Canadas-Godoy V, Pérez-Castellano N, Garofalo D, Salvador-Montañés O, Calvo CJ, Quintanilla JG, Peinado R, Mora-Jiménez I, Pérez-Villacastín J, Rojo-Álvarez JL, Filgueiras-Rama D. Safety threshold of R-wave amplitudes in patients with implantable cardioverter defibrillator. *Heart.* 2016;102(20):1662-70. Article. IF: 6.059; Q1
 - * Lincoff AM, Mehran R, Pocsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, López-Sendón J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. *Lancet.* 2016;387(10016):349-56. Article. IF: 47.831; D1
 - * Lobos-Bejarano JM, Barrios V, Polo-García J, Escobar C, Vargas-Ortega D, Marín-Montanes N, Prieto-Valiente L, Fuentes S, Prieto MA, García-Ortiz L. Evaluation of SAME-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. *Curr Med Res Opin.* 2016;32(7):1201-7. Article. IF: 2.757; Q1
 - * López MLP, Peinado AA, Rocafort AG, Zurita MB, Lois JR, Blanco FV, Ruiz JMO, Recalde AS. Surgical correction in adults with Fallot previously unoperated or just palliated: Fiction or reality? *Cir Cardiovasc.* 2016;23(1):24-30. Article. IF: Not Indexed
 - * López MLP, Peinado AA, Rocafort AG, Zurita MB, Lois JR, Pérez RS, Blanco FV, Ruiz JMO, Recalde AS. Surgical reinterventions in Fallot patients during adulthood: An emerging population. *Cir Cardiovasc.* 2016;23(5):220-8. Article. IF: Not Indexed
 - * López-Sendón JL, González-Juanatey JR, Pinto F, Castillo JC, Badimón L, Dalmau R, Torrecilla EG, Mínguez JRL, Maceira AM, Pascual-Figal D, Moya-Prats JLP, Sionis A, Zamorano JL. Quality markers in cardiology: measures of outcomes and clinical practice-a perspective of the Spanish Society of

Cardiology and of Thoracic and Cardiovascular Surgery. Eur Heart J. 2016;37(1):12-23. Article. IF: 19.651; D1

- * Lozano IF, Urkia C, Mesa JBL, Escudier JM, Manrique I, García ND, Vázquez AP, Sionis A, Osorio PL, Núñez M, de Sa EL. European resuscitation council guidelines for resuscitation 2015: Key points. Rev Esp Cardiol. 2016;69(6):588-94. Editorial Material. IF: 4.485; Q2
- * Lyden PD, López-de-Sa E, Nichol G, Kiragu AW. Current advances in the use of therapeutic hypothermia. Ther Hypothermia Temp Manag. 2016;6(1):2-5. Editorial Material. IF: 1.787; Q4
- * Manolis AJ, Poulimenos LE, Ambrosio G, Kallistratos MS, López-Sendón J, Dechend R, Mancía G, Camm AJ. Medical treatment of stable angina: A tailored therapeutic approach. Int J Cardiol. 2016;220:445-53. Review. IF: 6.189; Q1
- * Martín-Reyes R, Hernández JMD, Franco-Peláez J, López-Palop R, Arrieta MT, Santos IJA, Sáez PC, Sánchez-Recalde A, Peña JCS, Camarero TG, Brugaletta S, de Carlos FG, Piñero A, Sánchez DCS, Frutos A, Larraya GL, Navarro F, Farre J. The use of the acute Pd/Pa drop after intracoronary nitroglycerin infusion to rule out significant FFR: CANICA (Can intracoronary nitroglycerin predict fractional flow reserve without adenosine?) multicenter study. Catheter Cardio Inte. 2016;87(2):262-9. Article. IF: 2.602; Q2
- * McMurray JJV, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang YT, Shao Q, Tarnesby G, Massie BM, (Castro Conde A) . Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New Engl J Med. 2016;374(16):1521-32. Article. IF: 72.406; D1
- * Merino JL, Arceluz M, Delgado R, Falconi E, Cruz F, Vázquez CC, Ortega M. Sensitivity and accuracy of Sensitherm/Esotherm oesophageal temperature probe. Europace. 2016;18(3):468-9. Letter. IF: 4.53; Q1
- * Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, López-Sendón J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in total cardiovascular events with Ezetimibe/Simvastatin post-acute coronary syndrome the IMPROVE-IT Trial. J Am Coll Cardiol. 2016;67(4):353-61. Article. IF: 19.896; D1
- * O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KAA, Gutiérrez JAT, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, López-Sendón JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction a randomized clinical trial. JAMA-J Am Med Assoc. 2016;315(15):1591-9. Article. IF: 44.405; D1
- * Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L, (López Sendón JL). Performance and validation of a novel

- biomarker-based stroke risk score for atrial fibrillation. *Circulation*. 2016;134(22):1697-707. Article. IF: 19.309; D1
- * Ortiz MR, Roldán I, Bertoméu V, Muñiz J, Marín F, Anguita M. Structural heart disease in anticoagulated patients with nonvalvular atrial fibrillation: Prevalence and clinical profile in a Spanish Sample. *Rev Esp Cardiol*. 2016;69(10):986-90. Letter. IF: 4.485; Q2
 - * Peinado R, Ruiz-Mateos F, Izquierdo M, Arana E, Robledo M, Arias MA, Jiménez-Jáimez J, Rodríguez-Manero M, Chimeno J. Cardiac arrhythmias and pacing 2015: A selection of topical issues. *Rev Esp Cardiol*. 2016;69(2):167-75. Editorial Material. IF: 4.485; Q2
 - * Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KAA, Califf RM, (Merino JL). Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF. *J Am Heart Assoc*. 2016;5(3):e002197. Article. IF: 4.863; Q1
 - * Ponz I, López-de-Sa E, Armada E, Caro J, Blázquez Z, Rosillo S, González O, Rey JR, Monedero MD, López-Sendón JL. Influence of the temperature on the moment of awakening in patients treated with therapeutic hypothermia after cardiac arrest. *Resuscitation*. 2016;103:32-6. Article. IF: 5.23; D1
 - * Rabadán IR, Sánchez MA, Marín F, Quesada MA, Siles JC, Peinado R, Bertomeu V, Fillat AC, Badimón L, Muñiz J. Current antiarrhythmic therapy for nonvalvular atrial fibrillation in Spain. Data from the FANTASIIA Registry. *Rev Esp Cardiol*. 2016;69(1):54-60. Article. IF: 4.485; Q2
 - * Rao SV, Zeymer U, Douglas PS, Al-Khalidi H, White JA, Liu JY, Levy H, Guetta V, Gibson CM, Tanguay JF, Vermeersch P, Roncalli J, Kasprzak JD, Henry TD, Frey N, Kracoff O, Traverse JH, Chew DP, López-Sendón J, Heyrman R, Krucoff MW. Bioabsorbable intracoronary matrix for prevention of ventricular remodeling after myocardial infarction. *J Am Coll Cardiol*. 2016;68(7):715-23. Article. IF: 19.896; D1
 - * Rodríguez-Manero M, Abu Assi E, Sánchez-Gómez JM, Fernández-Armenta J, Díaz-Infante E, García-Bolao I, Benezet-Mazuecos J, Lahuerta AA, Expósito-García V, Bertomeu-González V, Arce-León A, Barrio-López MT, Peinado R, Martínez-Sande L, Arias MA. Comparative evaluation of four risk scores for predicting mortality in patients with implantable cardioverter-defibrillator for primary prevention. *Rev Esp Cardiol*. 2016;69(11):1033-41. Article. IF: 4.485; Q2
 - * Rodríguez-Manero M, Barrio-López MT, Abu Assi E, Expósito-García V, Bertomeu-González V, Sánchez-Gómez JM, González-Torres L, García-Bolao I, Gaztanaga L, Cabañas-Grandio P, Iglesias-Bravo JA, Arce-León A, la Huerta AA, Fernández-Armenta J, Peinado R, Arias MA, Díaz-Infante E. Primary prevention of sudden death in patients with valvular cardiomyopathy. *Rev Esp Cardiol*. 2016;69(3):272-8. Article. IF: 4.485; Q2

- * Salinas P, Moreno R, Calvo L, Sánchez-Recalde A, Jiménez-Valero S, Galeote G, López-Fernández T, Ramírez U, Riera L, Plaza I, Moreno I, Mesa JM, López-Sendón JL. Long-term follow-up after transcatheter aortic valve implantation for severe aortic stenosis. *Rev Esp Cardiol.* 2016;69(1):37-44. Article. IF: 4.485; Q2
- * Sánchez MA, Conde AC, Fort AC, Marimón XGM, Doblás JJG, González-Juanatey JR, Corbi RML, López-Sendón JL, Prieto JM, Padial LR. Challenges in oral lipid-lowering therapy: position document of the Spanish Society of Cardiology. *Rev Esp Cardiol.* 2016;69(11):1083-7. Editorial Material. IF: 4.485; Q2
- * Sánchez-Recalde A, Moreno R, Flores BE, Jiménez-Valero S, Mateos AGDY, López-Sendón JL. Percutaneous transcatheter treatment for massive pulmonary embolism. *Rev Esp Cardiol.* 2016;69(3):340-2. Letter. IF: 4.485; Q2
- * Sánchez-Recalde A, Moreno R, Jiménez-Valero S, Galeote G. Systemic thrombolysis for high-risk pulmonary embolism versus percutaneous transcatheter treatment. Response. *Rev Esp Cardiol.* 2016;69(8):801-2. Letter. IF: 4.485; Q2
- * Sanjuán P, Montalbetti T, Pérez-García AM, Bermúdez J, Arranz H, Castro A. A Randomised trial of a positive intervention to promote well-being in cardiac patients. *Appl Psychol Health Well Being.* 2016;8(1):64-84. Article. IF: 2.722; Q1
- * Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA, Lopes RD, Steg PG, Storey RF, Wallentin L, Cannon CP, (López-Sendón JL). Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. *Am Heart J.* 2016;177:1-8. Article. IF: 4.436; Q2
- * Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B, Schulte PJ, Storey RF, Wallentin L, Steg PG, James SK, (López Sendón JL). Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. *Heart.* 2016;102(8):617-25. Article. IF: 6.059; Q1
- * Weisz G, Genereux P, Iniguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW (Moreno Gómez R). Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet.* 2016;387(10014):136-45. Article. IF: 47.831; D1
- * Zeymer U, Montalescot G, Ardissino D, Bolognese L, Clemmensen P, Collet JP, López-Sendón J, Widimsky P. Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. *Eur Heart J Acute Cardiovasc Care.* 2016;5(3):282-8. Article. IF: Not Indexed

- * Zeymer U, Widimsky P, Danchin N, Lettino M, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, de Luca L, Dorler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Luscher TF, Matter CM, Montalescot G, Radovanovic D, Sendón JL, Tousek P, Weidinger F, Weston CFM, Zaman A, Andell P, Li J, Jukema JW. P2Y₁₂ receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. *Eur Heart J Cardiovasc Pharmacother*. 2016;2(4):229-43. Article. IF: Not Indexed